Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03632577
Other study ID # RC31/16/8769
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 19, 2017
Est. completion date October 15, 2019

Study information

Verified date November 2020
Source University Hospital, Toulouse
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Extubation stay at high risk of reintubation even scheduled and in the best condition of hematosis. Re-intubation's rate in main studies in chronic obstructive diseases reach to 20% and it is associated to a higher mortality, higher pneumonia under mechanic ventilation, and higher duration of hospitalization especially in intensive care units. Place of NIV in this situation is still on evaluation. A recent meta-analysis demonstrates that use of NIV in post-extubation in COPD seems to decrease re-intubation rate. HFO, thanks to its properties (oxygen, humidification and heat with high flow) could be useful in this population in ventilatory weaning. Compared to oxygen conventional therapy with high-concentration mask, HFO seems to be as efficient and better tolerated. A recent study shows that HFO is non-inferior to NVI in post-extubation in patient with high risk of re-intubation. Furthermore, oxygenation in post-extubation should be optimized to avoid hypoxemia and hypercapnia in this patient at risk of hypoventilation. Place of AFOT could improve hematosis by providing adapted flow of oxygen to each patient. The investigator choose the hypothesis for this study that HFO is as effective and tolerated in post-extubation than NIV with AFOT.


Description:

A recent meta-analysis demonstrates that use of NIV in post-extubation in obstructive chronic bronchopathies seems to decrease re-intubation rate. High Flow Oxygen, thanks to its properties (oxygen, humidification and heat with high flow) could be useful in this population in ventilatory weaning. Compared to oxygen conventional therapy with high-concentration mask, High Flow Oxygen seems to be as efficient and better tolerated . A recent study shows that High Flow Oxygen is non-inferior to Non Invasive Ventilation in post-extubation in patient with high risk of re-intubation. Furthermore, oxygenation in post-extubation should be optimized to avoid hypoxemia and hypercapnia in this patient at risk of hypoventilation.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date October 15, 2019
Est. primary completion date June 26, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient with respiratory disease suspected or proved (COPD, asthma, bronchiectasis, cystic fibrosis, interstitial pneumonia, obstructive insufficient respiratory, restrictive insufficient respiratory) when an extubation is scheduled. - Patient who signed the informed consent - Patient affiliated to social insurance Exclusion Criteria: - Pregnant woman - Terminal extubation - NIV at home before intubation (non-exclusion of continue positive airway pressure: CPAP) - Tracheotomy - Patient under trusteeship, guardianship or safeguard of justice

Study Design


Intervention

Device:
High Flow Oxygen (HFO)
HFO is a mix tap of air and oxygen. It permits to control FiO2 and generated controlled high flow air until 60/min. Air and oxygen are mixed, warmed, humidified and issued to patient by a warming monopod inspiratory circuit to nasal cannulas of a large diameter. Expiration is free.
Non Invasive Ventilation (NIV)
NIV was already evaluated in post-extubation. This technic is now used in daily consolidation processing after extubation because it provides a ventilator help with two levels of pressure helping in respiratory work. Adding Automated Flow Oxygen Titration could optimized patient's oxygenation and reduce workload of caregivers.

Locations

Country Name City State
France CHU Larrey Toulouse

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Toulouse

Country where clinical trial is conducted

France, 

References & Publications (5)

Bajaj A, Rathor P, Sehgal V, Shetty A. Efficacy of noninvasive ventilation after planned extubation: A systematic review and meta-analysis of randomized controlled trials. Heart Lung. 2015 Mar-Apr;44(2):150-7. doi: 10.1016/j.hrtlng.2014.12.002. Epub 2015 Jan 13. Review. — View Citation

Brotfain E, Zlotnik A, Schwartz A, Frenkel A, Koyfman L, Gruenbaum SE, Klein M. Comparison of the effectiveness of high flow nasal oxygen cannula vs. standard non-rebreather oxygen face mask in post-extubation intensive care unit patients. Isr Med Assoc J. 2014 Nov;16(11):718-22. — View Citation

Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, Prat G, Boulain T, Morawiec E, Cottereau A, Devaquet J, Nseir S, Razazi K, Mira JP, Argaud L, Chakarian JC, Ricard JD, Wittebole X, Chevalier S, Herbland A, Fartoukh M, Constantin JM, Tonnelier JM, Pierrot M, Mathonnet A, Béduneau G, Delétage-Métreau C, Richard JC, Brochard L, Robert R; FLORALI Study Group; REVA Network. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015 Jun 4;372(23):2185-96. doi: 10.1056/NEJMoa1503326. Epub 2015 May 17. — View Citation

Hernández G, Vaquero C, Colinas L, Cuena R, González P, Canabal A, Sanchez S, Rodriguez ML, Villasclaras A, Fernández R. Effect of Postextubation High-Flow Nasal Cannula vs Noninvasive Ventilation on Reintubation and Postextubation Respiratory Failure in High-Risk Patients: A Randomized Clinical Trial. JAMA. 2016 Oct 18;316(15):1565-1574. doi: 10.1001/jama.2016.14194. Erratum in: JAMA. 2016 Nov 15;316(19):2047-2048. Erratum in: JAMA. 2017 Feb 28;317(8):858. — View Citation

Tiruvoipati R, Lewis D, Haji K, Botha J. High-flow nasal oxygen vs high-flow face mask: a randomized crossover trial in extubated patients. J Crit Care. 2010 Sep;25(3):463-8. doi: 10.1016/j.jcrc.2009.06.050. Epub 2009 Sep 24. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Primary outcome: Tolerance of each dispositive Comfort scale (from 0 to 100 : 0 is totally uncomfortable - 100 : comfortable) Hours 0
Primary Primary outcome: Tolerance of each dispositive Comfort scale (from 0 to 100 : 0 is totally uncomfortable - 100 : comfortable) Hours 6
Primary Primary outcome: Tolerance of each dispositive Comfort scale (from 0 to 100 : 0 is totally uncomfortable - 100 : comfortable) Hours 24
Primary Primary outcome: Tolerance of each dispositive Comfort scale (from 0 to 100 : 0 is totally uncomfortable - 100 : comfortable) Hours 48
Secondary Dyspnea scale of Borg Dyspnea score which is a quantitative measure of the perception of effort during a physical exercise. The measure is a rating on a scale from 0 to 10 attached to different words of appreciation: "very light, difficult, painful ..." effort. This global measurement, based on the physical and psychological sensations of the person, takes into account the physical condition, the environmental conditions and the level of general fatigue. The scale between 0 and 10 was designed to approximate the heart rate of a healthy young adult (effort 8 represents 80% of the CF). Hours 6
Secondary Dyspnea scale of Borg Dyspnea score which is a quantitative measure of the perception of effort during a physical exercise. The measure is a rating on a scale from 0 to 10 attached to different words of appreciation: "very light, difficult, painful ..." effort. This global measurement, based on the physical and psychological sensations of the person, takes into account the physical condition, the environmental conditions and the level of general fatigue. The scale between 0 and 10 was designed to approximate the heart rate of a healthy young adult (effort 8 represents 80% of the CF). Hours 24
Secondary Dyspnea scale of Borg Dyspnea score which is a quantitative measure of the perception of effort during a physical exercise. The measure is a rating on a scale from 0 to 10 attached to different words of appreciation: "very light, difficult, painful ..." effort. This global measurement, based on the physical and psychological sensations of the person, takes into account the physical condition, the environmental conditions and the level of general fatigue. The scale between 0 and 10 was designed to approximate the heart rate of a healthy young adult (effort 8 represents 80% of the CF). Hours 48
Secondary Treatment's failure defined as use of NVI in HFO group or use of HFO in NVI group defined by reintubation or exchange of treatment or premature discontinuation of treatment Month 3
Secondary Hematosis : PaO2, PaCO2, pH Measurement of PaO2, PaCO2 and pH hours 6
Secondary Hematosis : PaO2, PaCO2, pH Measurement of PaO2, PaCO2 and pH hours 24
Secondary Hematosis : PaO2, PaCO2, pH Measurement of PaO2, PaCO2 and pH hours 48
Secondary Duration of hospitalization in intensive care units, reanimation, hospital after extubation. Measurement of hospitalization in intensive care units in days Month 3
Secondary Mortality in ICU (continuous monitoring unit) Measurement of mortality Month 3
Secondary Mortality in hospital Measurement of mortality Month 3
Secondary Mortality at M1 and M3 Measurement of mortality Month 1
Secondary Mortality at M1 and M3 Measurement of mortality Month 3
Secondary Use of another technic (HFO or NVI) in time Duration of use of the device (VNI, OHD) at H72 hours 72
Secondary Respiratory congestion (number of fibroscopy for airway's desobstruction, number of respiratory kinesitherapy consults, radiological atelectasis) Measurement of respiratory congestion by : number of fibroscopy for airway's desobstruction, number of respiratory kinesitherapy consults and radiological atelectasis month 3
Secondary New intubation rate at H48 New intubation rate at H48 Hours 48
Secondary New intubation rate at H72 New intubation rate at H72 Hours 72
Secondary SpO2 stability Percentage of time spent below 88% and above 92% of SpO2 hours 48
Secondary SpO2 stability Percentage of time spent below 88% and above 92% of SpO2 hours 72
See also
  Status Clinical Trial Phase
Withdrawn NCT03376204 - Pain Mechanisms in Patients With Bronchiectasis
Not yet recruiting NCT05902702 - Isotonic Saline for Children With Bronchiolitis N/A
Recruiting NCT05246098 - REVIVe: Frailty, Rehabilitation, and Outcomes in Critically Ill Adult and Pediatric Survivors of COVID-19 or ARI
Completed NCT04467190 - Investigation of Inflammacheck to Measure Exhaled Breath Condensate Hydrogen Peroxide in Respiratory Conditions
Not yet recruiting NCT05374148 - Respiratory Health Problems Among Workers in Ferrosilicon Alloys Industry in Aswan-Eygpt.
Recruiting NCT04502368 - Fiberoptic Bronchoscopy and Bronchoalveolar Lavage in Critically Ill Ventilated Patients
Recruiting NCT05775952 - Airway Remodeling and Rhinovirus in Asthmatics
Active, not recruiting NCT02681848 - What Are the Effects of Varenicline Compared With Nicotine Replacement Therapy on Long Term Smoking Cessation and Clinically Important Outcomes?
Recruiting NCT06002685 - Partners in Children's Health (CSN): A Randomized Trial of an Attachment Based Intervention N/A
Enrolling by invitation NCT03319446 - Collection of Anonymized Samples N/A
Recruiting NCT04287959 - SWISH Trial (Strategies for Weaning Infants on Supportive High Flow) N/A
Completed NCT05017727 - Closed-loop Oxygen Control in Ventilated Infants Born at or Near Term
Completed NCT04607330 - Protein Top-up Acceptability Study for Patients With Increased Protein Needs N/A
Completed NCT03334916 - A Clinical Trial to Evaluate the Efficacy and Safety of YMC026 in Respiratory Disease Patients Phase 4
Completed NCT04649736 - Home-based Respiratory Physiotherapy and Telephone-Based Psychological Support in Severe COVID-19 Patients N/A
Completed NCT03661801 - Novel Pleural Fluid, Biopsy and Serum Biomarkers for the Investigation of Pleural Effusions
Enrolling by invitation NCT03322254 - How Respiratory Pathogens Panel Results Affect Patients' Plan of Care
Recruiting NCT03937583 - Screening for Cancer in Patients With Unprovoked VTE Phase 4
Not yet recruiting NCT06026163 - Caffeine as an Adjuvant Therapy for Late Preterm Infants With Respiratory Distress Phase 2/Phase 3
Completed NCT04581096 - Mapping COVID-19 Spread in a Tertiary Hospital